What Is Myeloma Cast Nephropathy? Kidney Risks and Treatment Options

Multiple myeloma can harm the kidneys. One type of kidney problem is called cast nephropathy. This article explains what myeloma cast nephropathy is, how it affects kidney function, how doctors diagnose it, and what treatments may help protect the kidneys.

Cast nephropathy in multiple myeloma

Cast nephropathy is a type of sudden kidney injury. It can happen when myeloma cells make large amounts of free light chains, which are small parts of antibodies. 

When light chains build up in the kidneys, they can combine with a natural kidney protein to form thick clumps, or “casts.” These casts clog the kidney’s tiny tubes. This blockage can trigger inflammation and scarring, which can make kidney problems harder to reverse.

This condition is also called light chain cast nephropathy or myeloma kidney. It is a leading cause of acute kidney injury in people with myeloma. Kidney injury matters because it can affect survival, day-to-day well-being, and which treatment options are safe. 

If kidney numbers worsen quickly, this is not something to “watch-and-wait” on. Fast treatment that lowers light chains quickly can improve the chance of kidney recovery, especially in the first days and weeks after diagnosis. 

Symptoms and tests for cast nephropathy

Some people with myeloma cast nephropathy feel symptoms of kidney failure. These can include fatigue, nausea, and/or poor appetite. Others have no clear symptoms and only learn about kidney injury through lab tests.

Doctors often look at:

• Creatinine and estimated glomerular filtration rate (eGFR), which help show kidney function.
• Urine protein testing, including how much of the protein is albumin.
• Serum free light chain levels, which measure the myeloma proteins driving the problem.

A kidney biopsy is the most accurate way to confirm cast nephropathy and rule out other myeloma-related kidney problems. During a kidney biopsy, a doctor takes a small sample of kidney tissue. In some situations, doctors may strongly suspect light chain cast nephropathy based on very high free light chains and urine protein findings with low albumin, and may not do a biopsy. 

If your team recommends a kidney biopsy, it is usually to guide the fastest, safest plan and avoid treating the wrong kidney problem.

Myeloma cast nephropathy treatment focuses on speed

The key goal of myeloma cast nephropathy treatment is to lower the free light chains fast. Research shows that people are more likely to regain kidney function when treatment starts quickly and when the myeloma responds well early. In one long-term review of biopsy-confirmed cases, people who started myeloma treatment sooner were more likely to recover kidney function, and kidney recovery was linked with longer survival.

Common first treatment backbones often include a proteasome inhibitor plus a steroid, because these can work quickly and are commonly used to help with kidney impairment:

• Bortezomib with dexamethasone

Some treatment plans may add other medicines depending on the situation, such as:

• Cyclophosphamide
• Daratumumab (Darzalex, Johnson & Johnson)

If you are hospitalized or newly diagnosed with kidney injury, your team may push for a rapid treatment start. That urgency is based on how cast nephropathy works.

Filtering therapies may be used in select cases

Some centers use blood-filtering approaches to remove free light chains faster, such as plasmapheresis or special dialysis filters. Plasmapheresis is a procedure that removes and replaces the liquid part of the blood to clear harmful proteins. Special dialysis filters are designed with larger pores that can capture and remove more free light chains from the blood. 

Studies have had mixed results, and infection risk and other factors can matter. These approaches are usually considered add-ons, not replacements, because long-term improvement still depends on stopping light chain production with effective myeloma treatment. 

If your team discusses plasmapheresis or special dialysis filters, ask what goal they are targeting, such as a specific drop in free light chains, and how they will monitor the benefits and risks. 

Steps that support your kidneys during cast nephropathy

Along with myeloma therapy, supportive care can help reduce further kidney stress. Steps you can take include:

• Careful hydration when safe. It’s important to remember that too much fluid can be harmful for some people. Talk to your healthcare team about what your hydration goals should be.
• Avoid kidney-toxic medicines, such as nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.
• Manage high calcium, which can worsen dehydration and kidney strain.
• Tell your care team about your kidney problems before any scan. Contrast dyes in some scans can make kidney problems worse.
• Avoid high-dose diuretics unless truly needed. 

Some people need dialysis temporarily while treatment lowers light chains and the kidneys recover. Dialysis can be short-term, but longer dialysis dependence may suggest more lasting kidney damage. 

If you need dialysis now, it does not always mean it will be permanent. Ask your doctor how your light chain levels are changing and what that means for kidney recovery.

Key takeaways 

Myeloma cast nephropathy is a serious kidney complication caused by free light chains clogging and inflaming the kidney tubes. The best chance for kidney recovery comes from starting myeloma treatment and lowering light chains fast. 

Supportive steps like avoiding kidney-toxic medicines, managing dehydration and high calcium, and close lab monitoring can also make a meaningful difference. If you have questions, contact your myeloma specialist. 

Get the latest myeloma updates delivered to you! The HealthTree newsletter shares core education, research advances, and more directly to your inbox. 

SIGN UP TODAY

Sources:

• Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome
• Multiple myeloma with acute light chain cast nephropathy
• Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges